Literature DB >> 1512467

Lesional elastase activity in psoriasis, contact dermatitis, and atopic dermatitis.

O Wiedow1, F Wiese, V Streit, C Kalm, E Christophers.   

Abstract

Human leukocyte elastase (HLE) is a broad spectrum serine protease derived from neutrophils and macrophages. We developed an assay to determine HLE activity on the skin surface in patients with inflammatory skin diseases. HLE activity was absent in the skin of healthy controls. A massive increase of HLE activity was found in lesional skin of psoriasis (31 times), allergic contact dermatitis (55 times), and atopic dermatitis (35 times), but not in uninvolved skin of diseased patients. Therefore, this assay appears to represent a useful biochemical marker of epidermal inflammation. The presence of proteolytically active HLE in diseased epidermis, which is known to contain specific inhibitors of this enzyme, suggests a pathophysiologic role of this enzymatic activity in psoriasis, contact dermatitis, and atopic dermatitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1512467     DOI: 10.1111/1523-1747.ep12616644

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  11 in total

1.  Neutrophil elastase promotes myofibroblast differentiation in lung fibrosis.

Authors:  Alyssa D Gregory; Corrine R Kliment; Heather E Metz; Kyoung-Hee Kim; Julia Kargl; Brittani A Agostini; Lauren T Crum; Elizabeth A Oczypok; Tim A Oury; A McGarry Houghton
Journal:  J Leukoc Biol       Date:  2015-03-05       Impact factor: 4.962

Review 2.  The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core.

Authors:  J Schalkwijk; O Wiedow; S Hirose
Journal:  Biochem J       Date:  1999-06-15       Impact factor: 3.857

Review 3.  Putative roles of inflammation in the dermatopathology of sulfur mustard.

Authors:  F M Cowan; C A Broomfield
Journal:  Cell Biol Toxicol       Date:  1993 Jul-Sep       Impact factor: 6.691

4.  Ahp-Cyclodepsipeptide Inhibitors of Elastase: Lyngbyastatin 7 Stability, Scalable Synthesis, and Focused Library Analysis.

Authors:  Danmeng Luo; Hendrik Luesch
Journal:  ACS Med Chem Lett       Date:  2020-03-04       Impact factor: 4.345

5.  Lesional elastase activity in psoriasis. Diagnostic and prognostic significance.

Authors:  O Wiedow; F Wiese; E Christophers
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

6.  Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase.

Authors:  Letizia Crocetti; Igor A Schepetkin; Agostino Cilibrizzi; Alessia Graziano; Claudia Vergelli; Donatella Giomi; Andrei I Khlebnikov; Mark T Quinn; Maria Paola Giovannoni
Journal:  J Med Chem       Date:  2013-07-25       Impact factor: 7.446

7.  Suppressing IL-36-driven inflammation using peptide pseudosubstrates for neutrophil proteases.

Authors:  Graeme P Sullivan; Conor M Henry; Danielle M Clancy; Tazhir Mametnabiev; Ekaterina Belotcerkovskaya; Pavel Davidovich; Sylvia Sura-Trueba; Alexander V Garabadzhiu; Seamus J Martin
Journal:  Cell Death Dis       Date:  2018-03-07       Impact factor: 8.469

8.  Quality of life of psoriasis patients before and after balneo -- or balneophototherapy.

Authors:  Stefano Tabolli; Anna Calza; Cristina Di Pietro; Francesca Sampogna; Damiano Abeni
Journal:  Yonsei Med J       Date:  2009-04-30       Impact factor: 2.759

9.  Neutrophil elastase enhances the proliferation and decreases apoptosis of leukemia cells via activation of PI3K/Akt signaling.

Authors:  Rong Yang; Liang Zhong; Xiao-Qun Yang; Kai-Ling Jiang; Liu Li; Hao Song; Bei-Zhong Liu
Journal:  Mol Med Rep       Date:  2016-03-28       Impact factor: 2.952

10.  Identification of small-molecule elastase inhibitors as antagonists of IL-36 cytokine activation.

Authors:  Graeme P Sullivan; Pavel B Davidovich; Sylvia Sura-Trueba; Ekaterina Belotcerkovskaya; Conor M Henry; Danielle M Clancy; Anna Zinoveva; Tazhir Mametnabiev; Alexander V Garabadzhiu; Seamus J Martin
Journal:  FEBS Open Bio       Date:  2018-03-25       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.